Key Insights

Highlights

Success Rate

82% trial completion

Published Results

165 trials with published results (15%)

Research Maturity

478 completed trials (43% of total)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

9.5%

104 terminated out of 1100 trials

Success Rate

82.1%

-4.4% vs benchmark

Late-Stage Pipeline

10%

108 trials in Phase 3/4

Results Transparency

35%

165 of 478 completed with results

Key Signals

165 with results82% success104 terminated

Data Visualizations

Phase Distribution

809Total
Not Applicable (256)
Early P 1 (11)
P 1 (186)
P 2 (248)
P 3 (92)
P 4 (16)

Trial Status

Completed478
Recruiting189
Unknown165
Terminated104
Active Not Recruiting81
Not Yet Recruiting38

Trial Success Rate

82.1%

Benchmark: 86.5%

Based on 478 completed trials

Clinical Trials (1100)

Showing 20 of 20 trials
NCT07225127RecruitingPrimary

Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer 2

NCT07646847Not ApplicableRecruiting

A Study of a Side Effects and Resource Navigation Program for People With Cancer

NCT06963346Phase 1RecruitingPrimary

Study Investigating Intravesical HDAC Inhibition to Improve Response to Immuno-Oncology Agents

NCT05891171Phase 1Active Not Recruiting

Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers

NCT07735858Active Not RecruitingPrimary

Microfluidic Urinary Exosome-Based Diagnostic Model for Bladder Cancer

NCT07732686Not Yet Recruiting

Analysis of Breath Volatile Organic Compounds Using Mass Spectrometry

NCT07660055Phase 1Recruiting

Study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Patients With Solid Tumors

NCT07419295Phase 3RecruitingPrimary

A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)

NCT07727343Not ApplicableNot Yet RecruitingPrimary

AI-Guided TURBT for Bladder Cancer

NCT07129993Phase 2Recruiting

Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma

NCT06465069Phase 1Recruiting

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

NCT03915678Phase 2Active Not Recruiting

Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors

NCT07724886Not ApplicableNot Yet RecruitingPrimary

A Randomised Trial Investigating the Role of ERBT Plus Intravesical BCG in Intermediate-Risk or High-Risk NMBC

NCT03693014Phase 2Active Not Recruiting

A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors

NCT06910657Phase 1Recruiting

IDOV-Immune for Advanced Solid Tumors

NCT07277413Phase 1Recruiting

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

NCT07721935Recruiting

Development of an AI-Agent for Urological Disease Diagnosis and Treatment

NCT04081246Not ApplicableCompletedPrimary

Transurethral Modified En Bloc Resection For Large Bladder Tumours.

NCT07090499Phase 1Recruiting

A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

NCT07124000Recruiting

DESTINY-PANTUMOUR04

Scroll to load more

Research Network

Activity Timeline